DE10213762A1 - Neues costimulierendes Molekül und dessen Verwendung - Google Patents

Neues costimulierendes Molekül und dessen Verwendung

Info

Publication number
DE10213762A1
DE10213762A1 DE10213762A DE10213762A DE10213762A1 DE 10213762 A1 DE10213762 A1 DE 10213762A1 DE 10213762 A DE10213762 A DE 10213762A DE 10213762 A DE10213762 A DE 10213762A DE 10213762 A1 DE10213762 A1 DE 10213762A1
Authority
DE
Germany
Prior art keywords
sema4a
protein
cell
antibody
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10213762A
Other languages
German (de)
English (en)
Inventor
Hitoshi Kikutani
Atsushi Kumanogoh
Edward Leon Barsoumian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to DE10213762A priority Critical patent/DE10213762A1/de
Priority to PCT/EP2003/002785 priority patent/WO2003080673A1/en
Priority to JP2003578426A priority patent/JP2005538041A/ja
Priority to AU2003219068A priority patent/AU2003219068A1/en
Priority to EP03714841A priority patent/EP1490406A1/en
Priority to US10/401,053 priority patent/US20040052782A1/en
Publication of DE10213762A1 publication Critical patent/DE10213762A1/de
Priority to US11/625,386 priority patent/US20070237773A1/en
Priority to US11/668,121 priority patent/US20070160604A1/en
Priority to US11/741,133 priority patent/US20080058257A1/en
Priority to US12/128,658 priority patent/US20080317766A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
DE10213762A 2002-03-26 2002-03-26 Neues costimulierendes Molekül und dessen Verwendung Withdrawn DE10213762A1 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DE10213762A DE10213762A1 (de) 2002-03-26 2002-03-26 Neues costimulierendes Molekül und dessen Verwendung
PCT/EP2003/002785 WO2003080673A1 (en) 2002-03-26 2003-03-18 Costimulatory molecule and its use
JP2003578426A JP2005538041A (ja) 2002-03-26 2003-03-18 共刺激分子及びその使用
AU2003219068A AU2003219068A1 (en) 2002-03-26 2003-03-18 Costimulatory molecule and its use
EP03714841A EP1490406A1 (en) 2002-03-26 2003-03-18 Costimulatory molecule and its use
US10/401,053 US20040052782A1 (en) 2002-03-26 2003-03-27 Costimulatory molecules and uses thereof
US11/625,386 US20070237773A1 (en) 2002-03-26 2007-01-22 Human sema4a protein antibodies and uses thereof
US11/668,121 US20070160604A1 (en) 2002-03-26 2007-01-29 Methods of identifying compounds capable of modulating t cell immune responses involving sema4a protein
US11/741,133 US20080058257A1 (en) 2002-03-26 2007-04-27 Costimulatory Molecules and Uses thereof
US12/128,658 US20080317766A1 (en) 2002-03-26 2008-05-29 Costimulatory Molecules and Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10213762A DE10213762A1 (de) 2002-03-26 2002-03-26 Neues costimulierendes Molekül und dessen Verwendung

Publications (1)

Publication Number Publication Date
DE10213762A1 true DE10213762A1 (de) 2003-10-09

Family

ID=27816004

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10213762A Withdrawn DE10213762A1 (de) 2002-03-26 2002-03-26 Neues costimulierendes Molekül und dessen Verwendung

Country Status (5)

Country Link
EP (1) EP1490406A1 (https=)
JP (1) JP2005538041A (https=)
AU (1) AU2003219068A1 (https=)
DE (1) DE10213762A1 (https=)
WO (1) WO2003080673A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003686A (es) 2003-10-03 2007-03-01 Brigham & Womens Hospital Ligandos tim-3 y sus metodos.
TW200539890A (en) 2004-03-12 2005-12-16 Brigham & Womens Hospital Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
DE202006007590U1 (de) 2006-05-12 2006-12-14 Osaka University Verwendung einer Zusammensetzung, die Sema7A- und VLA-1-Interaktion inhibiert, zum Behandeln von Cytokin-vermittelten Erkrankungen
WO2008055889A1 (en) * 2006-11-10 2008-05-15 Osaka University Compositions and methods of treating oncological, inflammatory and autoimmune diseases mediated by sema4a

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538841A (ja) * 1999-03-18 2002-11-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２７個のヒト分泌タンパク質
US7033780B1 (en) * 1999-06-14 2006-04-25 Millennium Pharmaceuticals, Inc. Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein
WO2002006339A2 (en) * 2000-07-03 2002-01-24 Curagen Corporation Proteins and nucleic acids encoding same
WO2002062841A2 (en) * 2001-02-02 2002-08-15 Incyte Genomics, Inc. Secreted proteins

Also Published As

Publication number Publication date
JP2005538041A (ja) 2005-12-15
AU2003219068A1 (en) 2003-10-08
EP1490406A1 (en) 2004-12-29
WO2003080673A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
EP1017723B1 (de) Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung
DE69519513T2 (de) Verfahren zur modulation von "t-zell-anergy"
DE102016115246C5 (de) Neue t-zellrezeptoren und deren verwendung in immuntherapie
DE102016123859B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE69017753T2 (de) Tumor-Nekrosefaktor-Bindungsprotein II, seine Reinigung und spezifische Antikörper.
DE69535375T2 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
DE69533331T2 (de) Liganden zur induktion der antigen-spezifischen apoptose in t-zellen
DE60313859T2 (de) Induktion der anti-tumor-ctl-immunität durch in-vivo-aktivierung von 4-1bb und/oder cd40
DE69624436T2 (de) Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
DE69533984T2 (de) Verfahren zur anregung von t-zelltoleranz gegen ein gewebe- oder organtransplantat
DE60029304T2 (de) Aktivierung von regulatorischen t zellen durch ein alpha-melanocyten stimulierendes hormon
DE69333591T2 (de) CD40CR-Rezeptor und Liganden dafür
DE69925909T2 (de) T-zell inhibierende rezeptorzusammensetzungen sowie deren verwendung
DE102004063494A1 (de) Antikörper
CN102988959B (zh) Nkg2d的调节
DE69737969T2 (de) Dns-impfung zur einleitung einer suppressiven t-zell-antwort
EP1600460A1 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
EP0980390A2 (de) Human-cd28 spezifische monoklonale antikörper zur antigenunspezifischen aktivierung von t-lymphozyten
DE19821060A1 (de) Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
DE102017114737A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE10212108A1 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
DE69535713T2 (de) Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
DE10050935A1 (de) Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
DE69635639T2 (de) Interleukin-12-beta-Rezeptoren mit niedriger Bindungsaffinität

Legal Events

Date Code Title Description
8141 Disposal/no request for examination